LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

Search

Mirati Therapeutics Inc

Gesloten

SectorGezondheidszorg

0

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Belangrijke statistieken

By Trading Economics

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

-0.05% downside

Nieuwssentiment

By Acuity

9%

91%

9 / 371 Rangschikking in Healthcare

Mirati Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 sep 2025, 22:41 UTC

Belangrijke Marktbewegers

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

12 sep 2025, 16:04 UTC

Belangrijke Marktbewegers

Upexi Shares Climb on Solana Gains

12 sep 2025, 15:03 UTC

Belangrijke Marktbewegers

Allied Gaming & Entertainment Shares Surge Following Crypto Investments

12 sep 2025, 20:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

12 sep 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

12 sep 2025, 20:09 UTC

Winsten

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

12 sep 2025, 19:23 UTC

Marktinformatie

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 sep 2025, 19:16 UTC

Marktinformatie

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 sep 2025, 19:03 UTC

Marktinformatie

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

12 sep 2025, 18:59 UTC

Marktinformatie

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

12 sep 2025, 18:38 UTC

Marktinformatie
Winsten

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

12 sep 2025, 18:33 UTC

Marktinformatie

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

12 sep 2025, 18:22 UTC

Marktinformatie

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

12 sep 2025, 16:56 UTC

Marktinformatie

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

12 sep 2025, 16:22 UTC

Winsten

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

12 sep 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

12 sep 2025, 16:19 UTC

Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 sep 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

12 sep 2025, 16:11 UTC

Winsten

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

12 sep 2025, 15:37 UTC

Marktinformatie

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

12 sep 2025, 15:22 UTC

Marktinformatie

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

12 sep 2025, 15:07 UTC

Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 sep 2025, 14:34 UTC

Marktinformatie

Russia Sanctions Put Bid Back in Oil -- Market Talk

12 sep 2025, 14:10 UTC

Marktinformatie

Inflation Report Unlikely to Dissuade Canada From Rate Cut -- Market Talk

12 sep 2025, 13:58 UTC

Marktinformatie

Dollar Could Rise if Fed Sounds Cautious on Rate Cuts -- Market Talk

12 sep 2025, 13:58 UTC

Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Super Micro, Adobe, Microsoft, Figure Technology, and More -- Barrons.com

12 sep 2025, 13:57 UTC

Winsten

AbbVie Stock Hit a Record on 'Big Win' for Blockbuster Drug. The Case for Buying In. -- Barrons.com

12 sep 2025, 13:56 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

12 sep 2025, 13:56 UTC

Marktinformatie

Canadian Dollar Faces Further Weakness Vs Non-U.S. Dollar Currencies -- Market Talk

12 sep 2025, 13:54 UTC

Marktinformatie

U.S. Natural Gas Recovers Ground -- Market Talk

Peer Vergelijking

Prijswijziging

Mirati Therapeutics Inc Prognose

Koersdoel

By TipRanks

-0.05% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 58.67 USD  -0.05%

Hoogste 59 USD

Laagste 58 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Mirati Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

5 ratings

0

Buy

5

Hold

0

Sell

Sentiment

By Acuity

9 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

EBITDA

Operationele winst

$

Over Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.
help-icon Live chat